Pharvaris (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris (NASDAQ:PHVS) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 90,400 shares, a growth of 813.1% from the March 31st total of 9,900 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 102,500 shares, the short-interest ratio is currently 0.9 days.

Pharvaris Trading Up 7.2 %

PHVS stock traded up $1.52 during midday trading on Thursday, hitting $22.77. 82,367 shares of the company traded hands, compared to its average volume of 102,201. Pharvaris has a twelve month low of $7.93 and a twelve month high of $33.00. The business has a 50 day simple moving average of $23.55 and a 200-day simple moving average of $23.32.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, April 10th. The company reported ($0.80) earnings per share (EPS) for the quarter. Equities analysts predict that Pharvaris will post -2.2 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently made changes to their positions in the business. Blackstone Inc. acquired a new stake in Pharvaris in the 4th quarter valued at approximately $2,805,000. venBio Partners LLC increased its position in Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after acquiring an additional 654,832 shares during the period. Commodore Capital LP bought a new position in Pharvaris during the fourth quarter worth $22,440,000. Vivo Capital LLC acquired a new position in Pharvaris during the 4th quarter valued at $7,994,000. Finally, Hudson Bay Capital Management LP bought a new stake in Pharvaris in the 3rd quarter valued at $812,000.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. JMP Securities lifted their target price on shares of Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research note on Thursday, April 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $34.00 price objective on shares of Pharvaris in a research note on Monday. Finally, Wedbush reissued an “outperform” rating and set a $35.00 target price on shares of Pharvaris in a research report on Thursday, April 11th.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).